A$4m Share Placement
On 16 October 2017, Neurotech announced an oversubscribed Share Placement to raise A$4m at an issue price of A$0.20.
Neurotech is focused on the development and commercialisation of regulated medical solutions for diagnosis and treatment of neurological disorders. Its flagship device, Mente Autism, is an independently certified medical device that provides neurofeedback therapy to children on the autism spectrum at home.
Azure acted as lead manager to the Share Placement.